Abstract 1788P
Background
CHART trial has demonstrated the survival benefit of rezvilutamide plus androgen deprivation therapy (ADT) over bicalutamide plus ADT in treating patients with high-volume, metastatic hormone-sensitive prostate cancer (mHSPC). This post-hoc analysis aimed to evaluate the association between achievement of deep PSA decline with survival outcomes in patients with high-volume mHSPC in the CHART trial.
Methods
Patients with high-volume mHSPC were randomly assigned (1:1) to receive ADT plus either rezvilutamide or bicalutamide. PSA kinetics and the association between deep PSA decline (≤0.2 ng/ml) and radiographic progression-free survival (rPFS) and overall survival (OS) in two groups were evaluated.
Results
A total of 654 patients were included in the analysis, with 326 patients in the rezvilutamide plus ADT group, and 328 patients in the bicalutamide plus ADT group. The median PSA nadir levels were 0.02 ng/ml, and 0.68 ng/ml in two groups, respectively. At 6-month, 170 (52.15%) and 90 (27.44%) patients achieved a deep PSA decline, respectively. With a median follow-up of 29.3 months, patients who achieved a deep PSA decline at 6-month had longer rPFS (HR=0.359, 95%CI 0.238, 0.543, P<0.001) and OS (HR=0.339, 95%CI 0.212, 0.540, P<0.001) than those who did not achieve it in the rezvilutamide plus ADT group. Significantly, rezvilutamide plus ADT was found to significantly prolong rPFS compared to bicalutamide plus ADT, regardless of whether patients achieved deep PSA decline at 6-month (HR=0.462, 95%CI 0.283, 0.754, P=0.002) or not (HR=0.587, 95%CI 0.428, 0.804, P<0.001). Table: 1788P
PSA kinetics in CHART trial
| Variables | Rezvilutamide plus ADT (n=326) | Bicalutamide plus ADT (n=328) |
| PSA baseline (ng/ml), median (Q1, Q3) | 78.79 (12.82, 314.80) | 51.32 (8.08, 236.63) |
| PSA nadir (ng/ml), median (Q1, Q3) | 0.02 (0.00, 0.41) | 0.68 (0.08, 3.16) |
| Time to PSA nadir, day, median (Q1, Q3) | 308.0 (169.0, 634.8) | 167.0 (85.0, 281.0) |
| PSA nadir ≤0.2 ng/ml, n (%) | 224 (68.7) | 109 (33.2) |
| Time to PSA ≤0.2 ng/ml, day, median (Q1, Q3) | 392.0 (222.3, 671.0) | 238.0 (141.0, 393.0) |
| PSA ≤0.2 ng/ml at 3-month, n (%) | 125 (38.34) | 58 (17.68) |
| PSA ≤0.2 ng/ml at 6-month, n (%) | 170 (52.15) | 90 (27.44) |
| PSA ≤0.2 ng/ml at 12-month, n (%) | 201 (61.66) | 108 (32.93) |
Conclusions
Rezvilutamide plus ADT resulted in a deep PSA decline, which was associated with improved long-term survival in patients with high-volume mHSPC.
Clinical trial identification
NCT03520478.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
J. Lian, Q. Shi: Financial Interests, Personal, Full or part-time Employment: Jiangsu Hengrui Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
1219P - Artificial intelligence-based breast cancer detection facilitates automated prognosis marker assessment using multiplex fluorescence immunohistochemistry
Presenter: Tim Mandelkow
Session: Poster session 14
1220P - Comprehensive diagnose of programmed death-ligand 1 from two-dimensional to three-dimensional in breast cancer with computer-aided artificial intelligence system
Presenter: Yi-Hsuan Lee
Session: Poster session 14
1221P - The functional domain of BRCA1/2 pathogenic variants (PVs) as potential biomarkers of second tumor and domain-related sensitivity to PARP-inhibitors
Presenter: Lorena Incorvaia
Session: Poster session 14
1222P - Detection of androgen-receptor splice variant 7 messenger RNA in circulating tumor cells of prostate cancer by in vitro assay
Presenter: Hoin Kang
Session: Poster session 14
1223P - Homologous recombination deficiency (HRD) testing on ovarian cancer ascites: A feasibility study
Presenter: Alberto Ranghiero
Session: Poster session 14
1224P - Detection of circulating tumor DNA (ctDNA) in untreated patients (pts) with cancer: Implications for early cancer detection (ECD)
Presenter: Yoshiaki Nakamura
Session: Poster session 14
1225P - Combining ctDNA and tissue-based-genomic profiling in advanced cancer: A real-world evidence prospective study in non-Western patients treated at Gustave Roussy cancer campus
Presenter: Tony Ibrahim
Session: Poster session 14
1226P - Multi-site validation of a deep learning solution for HER2 profiling of breast cancer from H&E-stained pathology slides
Presenter: Salim Arslan
Session: Poster session 14
1227P - Novel in vivo photonics-immunoassay system, inPROBE, for the rapid detection of HER2 in breast cancer
Presenter: Magdalena Staniszewska
Session: Poster session 14
1228P - A circulating tumor cell (CTC) based assay for diagnostic immunocytochemistry profiling of lung cancer
Presenter: Nitesh Rohatgi
Session: Poster session 14